摘要由致病性基因组拷贝数变异(pathogenic copy number variation, pCNV)导致的染色体微缺失、微重复综合征是胎儿出生缺陷的一个重要遗传学病因。近年来随着染色体微阵列分析(chromosomal microarray analysis, CMA)和基于二代测序(next generation sequencing，NGS)的基因组拷贝数变异测序技术(copy number variation sequencing, CNV-seq)在产前诊断领域广泛应用，规范CNV分析流程和报告的重要性日益彰显。同时，对基因组纯合区域(regions of homozygosity，ROH)的分析和报告流程国内也亟需专业的指导意见。基于此，本组专家就CNV、ROH的数据分析流程、报告标准及报告内容等达成共识，以期规范CMA/CNV-seq等技术在产前诊断中的应用。

abstractsChromosomal microdeletions and microduplications have been proven to be a significant proportion of genetic factors underlying birth defects. Chromosomal microarray analysis (CMA) and next generation sequencing-based copy number variation (CNV-seq) assay have been recommended as first-tier tests for prenatal evaluation of disease-causing CNV across the genome. With the broad application of such technologies in prenatal genetic diagnosis, there is a needed to enhance the consistency in interpretation and reporting of CNV results in clinical laboratories across China. In addition, a standard guideline for prenatal analysis and reporting of regions of homozygosity (ROH) is also required. To assist the classification, interpretation and reporting of CNV/ROH, the following recommendations have been developed, which may enhance a standard application of CMA/CNV-seq techniques in prenatal genetic diagnosis.